Research Analysts Set Expectations for CADL FY2026 Earnings

Candel Therapeutics, Inc. (NASDAQ:CADL) – Brookline Capital Markets issued their FY2026 EPS estimates for shares of Candel Therapeutics in a note issued to investors on Wednesday, August 12th. Brookline Capital Markets analyst K. Dolliver expects that the company will earn ($1.28) per share for the year. The consensus estimate for Candel Therapeutics’ current full-year earnings is ($1.30) per share.

A number of other equities research analysts have also recently weighed in on the company. Bank of America increased their price target on Candel Therapeutics from $9.00 to $12.00 and gave the company a “neutral” rating in a research note on Friday, August 14th. UBS Group reaffirmed a “buy” rating on shares of Candel Therapeutics in a report on Monday. Stifel Nicolaus initiated coverage on Candel Therapeutics in a research report on Monday, July 13th. They issued a “buy” rating and a $22.00 target price on the stock. Wall Street Zen lowered Candel Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, August 16th. Finally, Zacks Research upgraded Candel Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Friday, May 15th. Eight equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $19.29.

Candel Therapeutics Price Performance

NASDAQ:CADL opened at $12.35 on Friday. Candel Therapeutics has a 12-month low of $4.35 and a 12-month high of $13.82. The firm has a market capitalization of $945.02 million, a price-to-earnings ratio of -8.76 and a beta of -0.51. The stock’s 50 day moving average price is $10.01 and its two-hundred day moving average price is $7.60. The company has a quick ratio of 16.09, a current ratio of 16.09 and a debt-to-equity ratio of 0.38.

Candel Therapeutics (NASDAQ:CADL) last issued its earnings results on Thursday, August 13th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.28).

Insiders Place Their Bets

In other Candel Therapeutics news, insider Francesca Barone sold 23,447 shares of Candel Therapeutics stock in a transaction on Monday, June 29th. The stock was sold at an average price of $10.06, for a total value of $235,876.82. Following the completion of the transaction, the insider directly owned 77,362 shares of the company’s stock, valued at $778,261.72. The trade was a 23.26% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CTO Seshu Tyagarajan sold 7,000 shares of the company’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $12.00, for a total value of $84,000.00. Following the sale, the chief technology officer owned 76,865 shares of the company’s stock, valued at approximately $922,380. The trade was a 8.35% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 37,447 shares of company stock worth $390,017. Corporate insiders own 14.30% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. BlackRock Inc. acquired a new position in Candel Therapeutics during the 2nd quarter worth approximately $51,181,000. Vanguard Group Inc. lifted its holdings in Candel Therapeutics by 12.3% during the 3rd quarter. Vanguard Group Inc. now owns 2,007,112 shares of the company’s stock worth $10,236,000 after buying an additional 219,563 shares during the period. Geode Capital Management LLC boosted its holdings in Candel Therapeutics by 5.3% in the fourth quarter. Geode Capital Management LLC now owns 977,512 shares of the company’s stock valued at $5,524,000 after acquiring an additional 49,315 shares during the last quarter. Halter Ferguson Financial Inc. increased its position in shares of Candel Therapeutics by 20.9% during the first quarter. Halter Ferguson Financial Inc. now owns 904,051 shares of the company’s stock worth $4,430,000 after buying an additional 155,996 shares during the period. Finally, State Street Corp lifted its stake in shares of Candel Therapeutics by 15.0% in the 4th quarter. State Street Corp now owns 792,218 shares of the company’s stock valued at $4,476,000 after purchasing an additional 103,452 shares during the period. Institutional investors and hedge funds own 13.93% of the company’s stock.

About Candel Therapeutics

Candel Therapeutics (NASDAQ:CADL) is a clinical-stage immuno-oncology company focused on the development of next-generation oncolytic viral therapies designed to treat solid tumors. The company’s lead candidate, CAN-2409, is a locally administered, gene-delivered viral therapy engineered to selectively replicate in cancer cells and induce immunogenic cell death. Candel leverages proprietary virus engineering platforms to enhance tumor-specific replication and stimulate anti-tumor immune responses, aiming to improve outcomes for patients with high unmet medical needs.

In addition to its lead program, Candel’s pipeline includes CAN-3110, an oncolytic herpes simplex virus targeting recurrent high-grade glioma, and other novel viral constructs being explored for a variety of solid tumor indications.